# CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours

Source: https://onco.cc/trials/nct06986811/  
OnCo record `nct06986811` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Standard surgery in childhood cancers, run by CEBIOTEX, now recruiting.

## Summary

CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours is a phase 2 interventional study registered as NCT06986811 by CEBIOTEX, with 60 participants planned, started 2025-05-06 and due to reach its primary completion in 2029-05. Interventions recorded: Standard surgery and CEB-01.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06986811
- Phase: 2
- Setting: First-in-paediatrics, Open Label, Exploratory, Externally Controlled Clinical Trial to Evaluate Safety, Efficacy and Pharmacokinetics of 7-ethyl-10-hydroxy Camptothecin (SN-38) Formulated as a Biocompatible Polymeric Nanofiber Membrane (CEB-01) for Treatment, in Addition to Standard of Care, of Paediatric Patients From Birth to Less Than 18 Years of Age With a Locally Resectable Tumours in Comparison to Standard of Care
- Sponsor: CEBIOTEX
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06986811: https://clinicaltrials.gov/study/NCT06986811

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- companies: [CEBIOTEX](https://onco.cc/companies/cebiotex/)

---
JSON: https://onco.cc/api/v1/entities/nct06986811.json